GSK will no longer supply or distribute Imvamune.



Bavarian Nordic agreed with GlaxoSmithKline not to pursue a collaboration for the production and marketing of Imvamune®, a third-generation smallpox vaccine under development.


The companies had previously signed a memorandum to ensure sufficient production capacity from several facilities and distribution of imvamune to various international markets at a time where Bavarian Nordic’s production facility was not established. Now Bavarian Nordic says it has the capacity to produce the expected RFP-III order.








This site uses Akismet to reduce spam. Learn how your comment data is processed.